A team from Crucell and Scripps has identified a trio of human mAbs that protect mice from influenza, including one that hits both A and B strains of the virus. Parent company Johnson & Johnson plans to develop the antibodies and in the long run could use the antibody against A and B strains as a guide for a universal flu vaccine.